Gufic BioSciences Ltd (GUFICBIO) is currently trading at 412.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gufic Biosciences Limited is an Indian pharmaceutical manufacturer specializing in sterile injectables and lyophilized products, operating legacy Navsari facilities and a newly commercialized Indore plant, and providing contract manufacturing, licensing and branded products across domestic and international markets. In Q1 FY27 Gufic reported consolidated revenues of INR260.8 crores, EBITDA of INR47.2 crores (18.09% margin) and PAT of INR22.46 crores (8.61% margin), marking year-on-year and sequential margin improvement driven by plant utilization gains, product-mix shift, and initial international fee income and CMO activity. The Indore facility is transitioning from baseline lyophilized volumes to higher-value capabilities: depot long-acting injectables, microsphere suites and lipid-based/liposomal formulations are being qualified and targeted to be operational during this financial year, enabling complex injectable production in-house. Strategically, Gufic is shifting some international markets from a distributor-led model to an IP-led front-end approach in selected emerging markets while continuing CMO partnerships like semaglutide with Hetero, and building licensing and contract manufacturing relationships to generate fee income alongside supply revenue. Management estimates current facilities can deliver roughly INR1,600–1,800 crores revenue without further capex (potentially up to ~INR2,000 crores with product-mix changes) and has set a baseline growth ambition of 15–20% year-on-year, positioning the company to expand margins via higher realization per vial and market expansion.

Over the past 52 weeks, Gufic BioSciences Ltd has traded between a low of ₹267.50 and a high of ₹466.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gufic BioSciences Ltd has a market capitalization of approximately 4,170.75. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gufic BioSciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 56.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,170.75 Cr, Gufic BioSciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gufic BioSciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gufic BioSciences Ltd is 56.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.